FP76
2141
Dr.Priya Chandil
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 2141 | Dr.Priya Chandil | drpriya.mys@gmail.com | 9739268383 |
Comprehensive Ophthalmology
Ophthalmic side effects of Anti-obesity drugs- An Emerging challange
PURPOSE:To review ophthalmic adverse effects of contemporary anti-obesity medications and their implications for clinical practice.METHODS: Narrative review of trials, studies, reviews, and case reports evaluating ocular complications associated with anti-obesity drugs.RESULTS: GLP-1 receptor agonists(Semaglutide)have been associated with early worsening of diabetic retinopathy due to rapid HbA1c reduction. Few case reports shows possible association with NAION. Topiramate-containing therapies can precipitate acute bilateral ACG and myopic shift through ciliochoroidal effusion, requiring immediate drug discontinuation and medical management. Phentermine may cause mydriasis, blurred vision, dry eye, and rarely precipitate angle closure in predisposed individuals. Long-term Orlistat use may lead to vitamin A deficiency, resulting in nyctalopia, xerophthalmia, and retinal dysfunction. .CONCLUSION:Timely screening of high risk cases will help in minimising ocular complications.
No Co-Author Selected